28/02/2023 – AB Science today announced publication of results from its positive pivotal phase 3 trial of masitinib in mild-to-moderate Alzheimer’s disease (AD) in Alzheimer’s Research & Therapy Download PDF Post navigationPreviousPrevious post:AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment BankNextNext post:AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001)Related PostsAB Science webcast – Masitinib in Sickle Cell DiseaseNovember 30, 2023AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell diseaseNovember 28, 2023The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”November 27, 2023Revenues for the first half of 2023 and update on AB Science’s activitiesSeptember 29, 2023Update on the EMA timetable for examination of the masitinib marketing authorization application in ALSSeptember 18, 2023AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)June 26, 2023
AB Science will host a live webcast on Thursday November 30, 2023, to present the masitinib development program in sickle cell diseaseNovember 28, 2023
The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”November 27, 2023
Update on the EMA timetable for examination of the masitinib marketing authorization application in ALSSeptember 18, 2023
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)June 26, 2023
